NEUROMUSCULAR PHARMACOLOGY
نویسندگان
چکیده
منابع مشابه
Sugammadex: another milestone in clinical neuromuscular pharmacology.
Sugammadex is a revolutionary investigational reversal drug currently undergoing Phase III testing whose introduction into clinical practice may change the face of clinical neuromuscular pharmacology. A modified gamma-cyclodextrin, sugammadex exerts its effect by forming very tight water-soluble complexes at a 1:1 ratio with steroidal neuromuscular blocking drugs (rocuronium > vecuronium >> pan...
متن کاملClinical pharmacology of neuromuscular blocking agents.
The clinical pharmacology of neuromuscular blocking agents is described. During neuromuscular blockade, succinylcholine attaches to receptors in the motor end plate and depolarizes the neuromuscular junction, making the end plate refractory to acetylcholine. The nondepolarizing relaxants have a structure similar to that of succinylcholine and bind to the same receptors. Instead of depolarizing ...
متن کاملChapter 22 – Neuromuscular Physiology and Pharmacology
The physiology of neuromuscular transmission could be analyzed and understood at the most simple level by using the classic model of nerve signaling to muscle through the acetylcholine receptor. The mammalian neuromuscular junction is the prototypical and most extensively studied synapse. Research has provided more detailed information on the processes that, within the classic scheme, can modif...
متن کاملThe Electrophysiology and Pharmacology of Lobster Neuromuscular Synapses
Effects of drugs on resting potential, membrane resistance, and excitatory and inhibitory postsynaptic potentials (e.p.s.p.'s and i.p.s.p.'s) of lobster muscle fibers were studied using intracellular microelectrodes Acetylcholine, d-tubocurarine, strychnine, and other drugs of respectively related actions on vertebrate synapses were without effects even in 1 per cent solutions (10(-)w/v). Gamma...
متن کاملThe pharmacology of atracurium: a new competitive neuromuscular blocking agent.
Atracurium besylate, 2,2'-(3,11-dioxo-4,10-dioxatridecylene)-bis-[6,7-dimethoxy-1-(3,4-dimethoxy-benzyl)-2-methyl-1,2,3,4-tetrahydroisoquinolinium] dibenzenesulphonate, is one of a new series of competitive neuromuscular blocking agents. An i.v. dose of 0.25 mg kg-1 produced complete paralysis in anaesthetized cats, dogs and rhesus monkeys; paralysis was of medium duration and was readily antag...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Anaesthesia
سال: 1980
ISSN: 0007-0912
DOI: 10.1093/bja/52.2.173